Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts

Drug and Alcohol Dependence

Volumn 50, Issue 3, 1998, Pages 221-226

  Petrakis, Ismene ^a,b   M Carroll, Kathleen ^a   Nich, Charla ^a   Gordon, Lynn ^a   Kosten, Thomas ^a   Rounsaville, Bruce ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Cocaine; Depression; Fluoxetine; Methadone; Opioid

Indexed keywords

COCAINE; DIAMORPHINE; FLUOXETINE; METHADONE; OPIATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MALE; METHADONE TREATMENT; OPIATE ADDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SYMPTOM; TOXICOLOGY;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BEHAVIOR, ADDICTIVE; COCAINE; COCAINE-RELATED DISORDERS; DEPRESSION; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HEROIN; HUMANS; MALE; METHADONE; NARCOTICS; OPIOID-RELATED DISORDERS; SUBSTANCE ABUSE DETECTION; TREATMENT OUTCOME;

EID: 0032078417     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(98)00032-5     Document Type: Article

References (29)

1. Batki SL, Manfredi LB, Sorensen JL, Jacob P, Dumontet R, Jones RT. Fluoxetine for cocaine abuse in methadone patients: preliminary findings. NIDA Res. Monogr. 105:1991;516-517.
2. Batki SL, Washburn AM, Delucchi K, Janes RT. A controlled trial of fluoxetine in crack and cocaine dependence. Drug Alcohol Depend. 41(2):1996;137-142.
3. Benefield P., Heel R.C., Lewis S.P. Fluoxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 32:1986;481-508.
4. Covi L., Hess J.M., Kreiter N.S., Haertzen C.A. Effects of combined fluoxetine and counseling in the outpatient treatment of cocaine abusers. Am. J. Drug Alcohol Abuse. 21:1995;327-344.
5. Ferguson J.M., Feighner J.P. Fluoxetine-induced weight loss in overweight non-depressed humans. Int. J. Obesity. 11(3):1987;163-170.
6. Fontaine R., Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder. J. Clin. Psychopharmacol. 6:1986;98-101.
7. Freeman C.P.I., Hamson M. Fluoxetine as a treatment for bulimia nervosa. Int. J. Obesity. 11(3):1987;171-177.
8. Goodnick P.J. Pharmacokinetics of second generation antidepressants: fluoxetine. Psychopharmacol. Bull. 27:1991;503-512.
9. Grabowski, J., 1995. Rhoades H, Elk Ronith, Schmitz, J., Davis, C., Creson, D., Kirby, K. Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials. J. Clin. Psychopharm. 14, 163-173.
10. Gram L. Fluoxetine. New Engl. J. Med. 331(20):1994;1354-1361.
11. Hedecker, D.H., 1993. MIXREG: A Fortran program for mixed-effects linear regression models (computer program). Rockville, MD, NIMH Division of Services Research, 1993.
12. Hubbard, R.L., Mardsen M.E., Rachal J.V. Drug Abuse Treatment: A National Study of Effectiveness. Chapel Hill, University of North Carolina Press, 1989.
13. Husband S.D., Marlowe D.B., Lamb R.J., Iguchi M.Y., Bux D.A., Kirby K.C., Platt J.J. Decline in self-reported dysphoria after treatment entry in inner-city cocaine addicts. J. Consult. Clin. Psychol. 65(1):1996;221-224.
14. Khantzian E.J., Treece C. DSM-III psychiatric diagnosis of narcotic addicts. Arch. Gen. Psychiatr. 42:1985;1067-1071.
15. Markovitz P.J., Calabrese J.R., Schulz S.C., Meltzer H.Y. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am. J. Psychiatr. 148:1991;1064-1067.
16. Mason B.J., Kocsis J.H., Ritvo E.C., Cutler R.B. A double-blind, placebo controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. J. Am. Med. Assoc. 275(10):1996;761-767.
17. McGrath P.J., Nunes E.V., Stewart J.W., Goldman D., Agosti V., Ocepek-Welikson K., Quitkin F.M. Imipramine treatment of alcoholics with primary depression: A placebo-controlled clinical trial. Arch. Gen. Psychiatr. 53(3):1996;232-240.
18. Nunes, E., Quitkin, F., Brady, R., Post-Koenig, T., 1994. Antidepressant treatment in methadone maintained patients. J. Addict. Dis. 13 (3), 13-24.
19. Petlier R., Schenk S. Effects of serotonergic manipulations on cocaine self-administration in rats. Psychopharmacology. 110:1993;390-394.
20. Petrakis I., Carroll K., Gordon L., Cushing G., Rounsaville B. Fluoxetine treatment for dually diagnosed methadone maintained opioid addicts: a pilot study. J. Addict. Dis. 13:1994;25-32.
21. Petrakis, I.L., Kosten, T.R. 1997. Clinical efficacy of pharmacotherapy. In: Johnson, B.A., Roache, J.D. (Ed.), Drug Addiction and its Treatment. Lippincott-Raven, Philadelphia, pp. 387-401.
22. Pollack M.H., Rosenbaum J.F. Fluoxetine treatment of cocaine abuse in heroin addicts. J. Clin. Psychiatr. 52(1):1991;31-33.
23. Ritz M.C., Cohen E.J., Kuhar M.J. Cocaine inhibition of ligand binding at dopamine and norepinephrine and serotonin transporters: a structure activity study. Life Sci. 46:1990;635-645.
24. Rounsaville B.J., Weissman M.M., Crits-Cristoph K., Kleber H.D. Diagnosis and symptoms of depression in opiate addicts: Course and relationship to treatment outcome. Arch. Gen. Psychiatr. 39:1982;151-156.
25. Schottenfield R.S., O'Malley S.S., Smith L., Rounsaville B.J., Jaffe J.H. Limitations and potential hazards of MAOIs for the treatment of depressive symptoms in abstinent alcoholics. Am. J. Drug Alcohol Abuse. 147:1990;76-82.
26. Spitzer R.L., Williams J.B., Gibbon M., First M.B. The structured clinical interview for DSM-III,R (SCID). I: History, rationale and description. Arch. Gen. Psychiatr. 49(8):1992;624-629.
27. Strain E.C., Stitzer M.L., Bigelow G.E. Early treatment time course of depressive symptoms in opiate addicts. J. Nerv. Mental Dis. 179(4):1991;215-221.
28. Walsh S.L., Preston K.L., Sullivan J.T., Fromme R., Bigelow G.E. Fluoxetine alters the effects of intravenous cocaine in humans. J. Clin. Psychopharmacol. 14:1994;396-407.
29. Ziedonis D., Kosten T.R. Depression as a protagonistic factor for pharmacological treatment of cocaine dependence. Psychopharmacol. Bull. 13:1991;13-24.